The core platform uses evanescent planar waveguide technology was developed by MBio. Products have been commercialized for applications outside of human health. Brava's first in vitro diagnostics applications will be for cardiac markers, a $2.3 billion worldwide market. Our first indications will be to assess chest pain and shortness of breath in the emergency department. The next assays will address sepsis, the highest cost disease state in U.S. health systems.

High Cost, High Incidence Diseases

Our initial products will address cardiovascular disease and sepsis.

Among the most prevalent of life-threatening diseases are heart attack and heart failure. According to the 2014 National Hospital Ambulatory Medical Care Survey, U.S. emergency departments ordered or ran 7.6 million cardiac enzyme tests to assess chest pain and 3.6 million BNP tests to diagnose heart failure. The worldwide market for cardiac markers was approximately $2.3 billion in 2016. Our initial cardiac marker assays will address the unmet need for rapid, accurate tests to manage these high-cost conditions.

Sepsis costs the U.S. health system $24 billion annually and is the most expensive condition to manage. There are approximately 5.3 million patients to screen in the U.S. alone. Brava tests are under development to differentiate bacterial from viral infections and to assess disease status.